![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
20
Zydus Lifesciences Limited Ankleshwar In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Atorvastatin calcium, Process I, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2011-181 - Rev 01
This Chemical Type CEP, issued on March 02, 2018, remains in force until April 12, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2191 associated with this CEP further emphasizes